US Pharma MarketingThe post Alkermes’ alixorexton secures FDA and EC orphan designations appeared first on Clinical Trials Arena.
Alkermes’ alixorexton secures FDA and EC orphan designations
Alkermes has received ODD from both the FDA and the EC for alixorexton, its investigational OX2R agonist to treat idiopathic hypersomnia and narcolepsy. The post Alkermes’ alixorexton secures FDA and EC orphan designations appeared first on Clinical Trials Arena .
Alkermes has received ODD from both the FDA and the EC for alixorexton, its investigational OX2R agonist to treat idiopathic hypersomnia and narcolepsy.
Source: Clinical Trials Arena